Immuneering Corporation(IMRX)

Description: Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, Immuneering has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering’s current development programs in oncology are focused on providing potential treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Immuneering’s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Additionally, Immuneering has six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage.

---

Keywords: Biopharmaceutical Biology Solid Tumors Oncology Neuroscience Drug Development Bioinformatics Advanced Solid Tumors Signal Transduction mTOR

---

Home Page: immuneering.com

IMRX Technical Analysis

245 Main Street
Cambridge, MA 02142
United States
Phone: 617 500 8080

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)